cyrilzakka/clinical-trials huggingface dataset:
Blood Virome After Haploidentical Hematopoietic Stem Cell Transplantation, a Pilot Study

The goal of this observational study is to assess the risk of viral infections in patients receiving hematopoietic stem cell transplantation (HSCT) from a haploidentical donor compared to those who receive HSCT from a HLA-matched donor. The main question it aims to answer is: to describe which viruses are replicating in the blood of the above two patient groups on the day of transplantation and at 1, 3 and 6 months after transplantation. Blood samples taken as part of routine care on the day of transplantation and at 1, 3 and 6 months post-transplantation visits are analyzed and the types and amount of viruses detected in the two groups of patients are described.

Geneva University Hospitals are one of the three centers performing allogeneic HSCT in Switzerland. Since several years the Division of infectious diseases runs a collaborative research program with the Division of Hematology. In 2015 the two divisions jointly created a prospective cohort of allo-HSCT patients called: "Infectious diseases in hematopoietic stem cell transplant patients cohort" enrolling potentially all adult patients engrafted in our center since 2015 (CCER protocol 15-120 and relative amendments). The cohort compiles clinical data on hematological and infectious complications occurring up to one year after transplantation and biological specimen collected systematically until up to 2 years after transplantation, which are stored in a joint biobank.

Eligibility Criteria:
Inclusion Criteria:

* Adult patients receiving allogeneic stem cell transplantation at the Geneva University Hospitals from a haploidentical or from an HLA-matched donor, who signed the informed consent form before transplantation for inclusion in the prospective cohort of "Infectious disease in hematopoietic stem cell transplant patients".

Exclusion Criteria:

* None
Antiarrhythmic Effects of N-3 Fatty Acids

To determine the antiarrhythmic effects of dietary N-3 fatty acids in patients with implanted defibrillators.

BACKGROUND:

Ventricular tachycardia (VT) and ventricular fibrillation (VF) are common causes of the 300,000 sudden deaths occurring in the United States each year. Most of these victims have associated heart disease, most commonly coronary artery disease. Populations consuming considerable quantities of fish and marine mammals have lower than expected mortality rates from coronary disease. Interventional and observational trials have indicated that fatty fish consumption decreases the death rate from coronary artery disease, in part by reducing the number of sudden deaths. Animal and tissue culture studies both support the hypothesis that these beneficial effects are from the antiarrhythmic properties of n-3 long chained polyunsaturated fatty acids (eicosapentaenoic and docosahexaenoic acids).

DESIGN NARRATIVE:

Prospective, randomized, double blinded trial. Survivors of VT and VF with an implantable defibrillator were randomized, 100 to dietary supplementation with n-3 polyunsaturated fatty acids(PUFA) or 100 to a placebo. Adherence to the supplement were assessed by measurements of plasma, red cell, and adipose tissue n-3 fatty acid concentrations. The primary outcome variable was the incidence of recurrent VT or VF, but secondary variables were also assessed using serial implantable cardioverter defibrillator (ICD) assessment, correlation of the rhythms with the biochemical measurements of n-3 fatty acids, hospitalization rates and quality of life. The (ICD) was the best protection available to patients and stored rhythm electrograms which allowed documentation of rhythm endpoints.

The study completion date listed in this record was obtained from the "End Date" entered in the Protocol Registration and Results System (PRS) record.

Eligibility Criteria:
No eligibility criteria
Evaluation of Auditory Fatigue in Medical Regulation Assistants

Auditory monitoring of employees is currently based on pure-tone audiometry. However, this clinical examination does not prevent from deafness but established it a posteriori. From a preventive standpoint, it is important to detect hearing professional pain before the development of irreversible(s) clinical(s) symptom(s). The investigators' hypothesis is that auditory fatigue results from damages of primary and secondary central auditory pathways involving cognitive processes.

The assessment of auditory fatigue includes the evaluation of speech intelligibility, short-term memory, working memory and perceived mental task load. The main objective of this study is to identify, among regulating medical assistants working with headset, a central auditory fatigue.


Eligibility Criteria:
Inclusion Criteria:

* Participants without hearing loss and without ontological antecedents in the past 5 years
* Participants gave their written informed consent
* Participants are affiliated to the french social welfare
* Preliminary clinical examination

Exclusion Criteria:

* Ontological antecedents in the past 5 years
* Pathology of the external or middle ear
* Abnormality in audiometric examination
* Participants already enrolled in an other research protocol
* Participants covered by articles L.1121-5 à L.1121-8 et L.1122-1-2 of the French Public Health Code
Evaluating the Utility of the Apoptosis Imaging Biomarker 18F]ML10 in Patients With Non-Hodgkin's Lymphoma(NHL)

This study aims to evaluate the potential of 2-(5- Fluoro pentyl)-2-methyl malonic acid (\[18F\]ML10), as an apoptosis imaging biomarker and its potential to predict response in patients with Non Hodgkin's Lymphoma.

Apoptosis or programmed cell death mechanisms are disrupted in cancer cells allowing them to live longer and grow faster than normal cells. Apoptosis is a key target for several novel anti-cancer agents. A biomarker that could permit imaging levels of ongoing apoptosis could be a powerful tool in associated drug development programs by providing relevant data to support proof of concept. In addition, use in the clinical setting may permit the tailoring of treatment for individual patients balancing efficacy of treatment with known toxicity levels. This study aims to evaluate the potential of 2-(5- Fluoro pentyl)-2-methyl malonic acid (\[18F\]ML10), as an apoptosis imaging biomarker and its potential to predict response in patients with Non Hodgkin's Lymphoma. All patients will have a baseline \[18F\]ML10 PET-CT scan and a post-treatment scan after the initiation of the first course of intravenous chemotherapy. The study aims to enrol unto 16 subjects with Non-Hodgkins Lymphoma.

Eligibility Criteria:
Inclusion Criteria:

1. Capable of giving written informed consent, and willing and able to comply with the requirements and restrictions listed in the consent form.
2. Male or female patients \>18 years of age at screening with histological or cytological diagnosis of Non-Hodgkin's Lymphoma and due to receive intravenous chemotherapy for the first time
3. A female subject is eligible to participate if she has non-childbearing potential
4. Male subject must agree to use one of the contraception methods listed
5. Able to lie comfortably on back for up to 70 minutes at a time.
6. WHO performance status 0, 1 or 2 -

Exclusion Criteria:

1. Patients with known history of Hepatitis B, C, non-A, non-B and HIV
2. Any clinically significant medical conditions that in the opinion of the investigator would compromise the compliance with study procedures.
3. Pregnant or breast feeding females.
4. Any other prior anticancer therapy
5. Any new investigational agent, including an investigational anti-cancer agent
6. History of sensitivity to heparin or heparin-induced thrombocytopenia.
7. Males and females not able to comply with contraceptive guidelines during the study.

   -
Effect of Compression Dressing After Upper Eyelid Blepharoplasty on Edema, Ecchymosis, Pain and Ocular Surface Irritation

Study to analyze whether there is a difference in postoperative outcome regarding edema, ecchymosis, pain, OSI and discomfort of the patients after blepharoplasty if a compression dressing is used or not.


Eligibility Criteria:
Inclusion Criteria:

* Patients with upper eyelid dermatochalasis who were scheduled for upper eyelid blepharoplasty

Exclusion Criteria:

* previous surgery on the upper eyelid, previous eye lid trauma, congenital lid changes, blepharochalasis syndrome, coagulation disorders or indication for combined ptosis and blepharoplasty surgery
Open-label Study to Evaluate Nerindocianine as a Surgical Aid in Ureter Delineation During Minimally Invasive Surgery

Phase 2, multicenter, efficacy and safety study evaluating the use of nerindocianine for the delineation of abdominopelvic ureter anatomy via near infrared fluorescence imaging during minimally invasive lower abdominal surgery (e.g. gynecological, lower gastrointestinal, or other lower abdominal surgery).

The primary objective of this study is to assess the acceptance of near-infrared (NIR) fluorescence imaging (650 to 900 nm) compared to white light (WL) using 3 3-point Likert scales.

Eligibility Criteria:
Inclusion Criteria:

* Provide written informed consent prior to the initiation of study procedures.
* At least 18 years of age.
* Consent to undergo minimally invasive, lower pelvic surgery.

Exclusion Criteria:

* Unwilling or unable to provide informed consent.
* Unwilling or unable to comply with the requirements of the protocol.
* Females who are pregnant, lactating, or planning a pregnancy throughout the study.
* Patients administered indocyanine green (ICG) at the same time of the lower pelvic surgery.
* Have known allergies to D-mannitol and/or citric acid.
* Participation in another clinical trial involving a drug in the past 12 weeks.
* Any other condition that, in the investigator's judgment, would potentially compromise the study compliance or the ability to evaluate safety or efficacy of the investigational product, or determined not a safe candidate for surgery based on standard of care for current medical condition.
The Relationship Between Trunk Muscle Endurance and Physical Activity, Low Back Pain and Fatigue in Young Adults

The trunk is a kinetic link that facilitates the transmission of force and angular moments between the lower and upper extremities, provides proximal stability for distal mobility, and maintains balance by keeping the body weight within the support surface.While trunk muscle strength is important for maintaining daily living activities, trunk muscle endurance plays an important role in preventing injuries by stabilizing the spine during long-term physical activity and sports activities (2).Decreased trunk muscle endurance can result in fatigue and low back pain. Low back pain is a major public health problem worldwide. In modern industrial society, the number of low back pain patients is increasing due to sedentary lifestyles, lack of exercise and working conditions.The lifetime prevalence of low back pain has been reported as 84%.80% of low back pain is nonspecific, that is, muscle weakness and ligament-related reasons for unknown reasons(3,4).Increasing the endurance of the waist muscles with exercise is used in the treatment of low back pain. From this point of view, while planning our study, we wanted to evaluate whether the decrease in trunk muscles is associated with low back pain and fatigue in young adults.

Our research will be carried out in healthy youngs adult volunteers between the ages of 18-24.It is a non-invasive cross-sectional observational study without a control group.

No device will be used.The following measurement and evaluation methods will be applied to all individuals who voluntarily agree to participate in the research.First, demographic data will be collected with the Patient Evaluation Form. For trunk endurance measurement, McGill Trunk Muscle Endurance Tests, Modified Biering-Sorensen test and Lateral bridge test will be used.These tests measure muscle strength in seconds with examination as described below and do not require a device.Fatigue severity scale and Roland Morris Disability Form will be filled to evaluate fatigue and lumbar network.Physical Activity level will be measured with the International Physical Activity Scale.

Eligibility Criteria:
Inclusion Criteria:

-Voluntarily agree to participate in the research

Exclusion Criteria:

* History of musculoskeletal surgery in the last 1 year
* Diagnosis of lumbar disc herniation, spondylolisthesis, knee ligament and connective tissue damage
* Scoliosis
* Pregnancy
* Malignancy and inflammatory disease
ME/CFS, Hypermobility and Craniocervical Obstructions

A retrospective study on clinical and radiological findings in ME/CFS


Eligibility Criteria:
Inclusion Criteria:

Patients at a multidisciplinary specialist clinic accepting to participate

Exclusion Criteria:

none
The Related Factors With Resilience in Caregivers Whose Child With Leukemia

The purpose of this study was to explore caregivers stress, family functioning, social support and family resilience of families whose children had acute lymphoblastic leukemia. The significantly correlation among caregivers stress, family functioning, social support and family resilience was also explored.


Eligibility Criteria:
Inclusion Criteria:

1. Diagnosed as acute lymphoblastic leukemia children, children with cancer are still alive and the age of 18 years of age.
2. Has been completed to guide the treatment regimen were in remission.
3. Caregiver can or Taiwanese language communicator.

Exclusion Criteria:

- Children with metastatic cancer who end chemical treatment of more than one year
Trial of an Herb and Mineral Combination Product on Fasting Glucose in Adults at Risk for Developing Diabetes

This is a multi-center, randomized, double-blind, placebo-controlled study in approximately 104 subjects (52 per group) to evaluate the effectiveness of an herb and mineral combination product on fasting serum glucose levels in subjects with impaired fasting glucose. The study consists of 5 visits: a Screening visit, followed by a Baseline visit (at which eligible subjects will be randomized to product to consume throughout the 12-week supplementation period), followed by Supplementation period visits at 3, 6 and 12 weeks after baseline.

The target population of this clinical trial is otherwise healthy, pre-diabetic adults who present with impaired fasting glucose.

Eligibility Criteria:
Inclusion Criteria:

* Be male or female, at least 18 years of age
* If age ≥45 years, must have a body mass index ≥ 25 kg/m2
* If age \<45 years, must have a body mass index ≥ 25 kg/m2 AND present with at least one additional risk factors for developing diabetes.
* Agree to use contraception throughout study period, unless postmenopausal or surgically sterile (women only)
* Be able to understand the nature and purpose of the study including potential risks and side effects
* Be willing to consent to study participation and to comply with study requirements
* Have a finger stick fasting blood glucose between 105 and 140 mg/dL and a serum fasting glucose between 100 and 125 mg/dL, measured at screening

Exclusion Criteria:

* Have diabetes (type I or II) or an HBA1c measurement \>6.5% at any time in the past or at the screening visit
* Have been taking within 2 weeks of screening any dietary supplement including vitamin and mineral complexes; herbal supplements; fish oil; fiber supplements; or any herbal ingredient/product that significantly affects glucose metabolism
* Have been taking within 4 weeks of screening any prescription or over-the-counter (OTC) medication that significantly affects glucose metabolism, including but not limited to, sulfonylureas, meglitinides, biguanides, thiazolidinediones, alpha-glucosidase inhibitors, Inhibitors of dipeptidyl peptidase 4 (DPP-4 inhibitors), systemic corticosteroids
* Daily use of non-steroidal anti-inflammatory drugs (NSAIDS) (daily baby aspirin use and continuous use of NSAIDS for 3 days or less for acute aches and pains are acceptable)
* Any co-morbidity or treatment that could, in the opinion of the investigator, preclude the subject's ability to successfully and safely complete the study or that may confound study outcomes
* Anticipated changes in dietary patterns or physical activity levels during the study, including attempts at body weight reduction
* Eating disorder
* Polycystic ovary syndrome
* Known allergies or intolerance to any substance in the study product
* Are pregnant or breastfeeding women
* History of alcohol, drug, or medication abuse
* Have participated in another study with any investigational product within 1 month of screening
* Had a recent (\<3 months) gastrointestinal surgery or any planned surgery during the clinical study
Effects of Biofeedback-based Music Program Using a Smart Device Application on Perioperative Sleep Quality

The purpose of this study is to investigate whether the effects of biofeedback-based music programs using a smart device application can improve perioperative sleep quality in patients undergoing breast cancer surgery.

In a biofeedback-based music group, the patient performs an active respiratory intervention session, which induces a slow breathing pattern. If breathing has been slow enough, the automatic mode is activated to provide music based on the patient's own breathing pattern. The investigators will provide biofeedback-based music, which incorporates the patient's respiratory information, while no intervention will be performed in the control group.

Eligibility Criteria:
Inclusion Criteria:

* Patients undergoing elective breast cancer surgery

Exclusion Criteria:

* Patients' refusal
* Day surgery or urgent surgery
* BMI ≥35
* Neurocognitive impairment, hearing disorder (ex : (dementia, impaired cognitive dysfunction, cerebral infarction, transient cerebral ischemic attack))
* Patients with psychiatric diseases, psychological drug intake
* Pre-existing conditions associated with sleep disorders or drug intake related to sleep
Dexmedetomidine Versus Midazolam Added to Ketamine in Pediatric Patients Undergoing Bone Marrow Aspiration and Biopsy

Group I :The patients will receive midazolam intravenously (i.v.) in a dose of 0.05 mg/kg diluted by 50ml saline over 10 minutes using syringe pump plus 1 mg/kg ketamine (iv).

Group II : The patients will receive Dexmedetomidine intravenously (i.v.) in a dose of 2mic/kg diluted by 50ml saline over 10 minutes using syringe pump plus 1 mg/kg ketamine (iv).

The objective of this study to evaluate the clinical effects, adverse effects and recovery time of two different sedative agents (midazolam and Dexmedetomidine) combined with ketamine during conscious sedation for child patient with haematological cancer undergoing BMA \&biopsy.


Eligibility Criteria:
Inclusion Criteria:

* All consecutive children with acute lymphoblastic leukemia undergoing bone marrow aspiration and biopsy.

Exclusion criteria:

* previous sensitization or anaphylactic reaction to Dexmedetomidine, ketamine,and midazolam;
* evidence of head injury,
* raised intracranial or intraocular tension;
* use of drugs known to interact with either study agent;
* an American Society of Anesthesiologists (ASA) physical status score greater than 2.
* Also Patients with cardiovascular, respiratory, hepatic diseases and epilepsy will be excluded.
Efficiency of Use of Baracetinib in Treatment of Lupus Nephritis

Patients with systemic lupus erythematosus have substantial unmet medical need. Baricitinib is an oral selective Janus kinase (JAK)1 and JAK2 inhibitor that we hypothesised might have therapeutic benefit in patients with systemic lupus erythematosus and had a diagnosis of systemic lupus erythematosus, and had active renal disease as defined by Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K). Efficacy and safety analyses included all patients who received at least one dose of study drug.

Patients with systemic lupus erythematosus have substantial unmet medical need. Baricitinib is an oral selective Janus kinase (JAK)1 and JAK2 inhibitor that we hypothesised might have therapeutic benefit in patients with systemic lupus erythematosus and had a diagnosis of systemic lupus erythematosus, and had active renal disease as defined by Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K). Efficacy and safety analyses included all patients who received at least one dose of study drug.

The baricitinib 4 mg dose suggestive to significantly improved the signs and symptoms of active systemic lupus erythematosus in patients who were not adequately controlled despite standard of care therapy, with a safety profile consistent with previous studies of baricitinib. This study provides the idea for future trials of JAK1/2 inhibition with baricitinib as a new potential oral therapy for

Eligibility Criteria:
Inclusion Criteria:

* lupus nephritis

Exclusion Criteria:

* cardiac disease Thrombosis
Comparison of Secretin-enhanced Magnetic Resonance Cholangiopancreatography (S-MRCP) to Endoscopic Pancreatic Function Test (ePFT) in Diagnosing Pancreatic Exocrine Insufficiency

The aim of our study is to evaluate S-MRCP, in comparison to direct pancreatic function, to measure pancreatic exocrine function in patients who have symptoms suspicious for insufficiency. We hypothesize that S-MRCP imaging parameters will correlate well with the direct pancreatic exocrine functioning.

Surgical resection offers the only hope of cure for pancreatic adenocarcinoma. While perioperative mortality rates have declined in recent years, pancreatic resection is still associated with significant postoperative malnutrition, maldigestion, and glucose intolerance, mostly as a result of pancreatic insufficiency. Quantifying individual pancreatic function remains a challenge, but is essential in improving the survival and quality of life of pancreatic cancer patients. Secretin-enhanced magnetic resonance cholangiopancreatography (S-MRCP) has recently emerged as a widely-accepted noninvasive technique to assess morphological changes in pancreatic ducts, as well as functional secretory capacity of the gland. The aim of our study is to evaluate S-MRCP as a means to evaluate for pancreatic exocrine insufficiency. This will be a prospective study of twelve patients who have undergone pancreatic resection and who have symptoms of abdominal pain, steatorrhea or weight loss. We will be comparing quantitative parameters of S-MRCP (maximal change in pancreatic duct diameter and volume before and after secretin administration) with endoscopic pancreatic function testing (maximal bicarbonate concentration in duodenal aspirate after secretin administration).

Eligibility Criteria:
Inclusion Criteria:

* 18 years of age and older
* Tissue-confirmed diagnosis of pancreatic adenocarcinoma
* Undergone surgical resection for adenocarcinoma no less than 3 months prior to enrollment
* Report significant abdominal pain/bloating or steatorrhea \>3x/week or demonstrate weight loss corresponding to \>10% of pre-surgery BMI.
* Scheduled for EGD/EUS to investigate the above clinical indicators.

Exclusion Criteria:

* History of any radiation therapy to the abdomen prior to surgery
* Any contraindication to MRI, including but not limited to implanted metal devices (e.g. pacemaker, berry aneurysm clips, neural stimulator, cochlear implants, or metal in the eye)
* Presence of pancreatic duct stent
* Treatment with an investigational drug within 1 month prior to the day of the study drug administration
* Current enrollment in any other interventional study
* Creatinine greater than 2.0
* Significant liver disease, liver masses, or evidence of portal hypertension
* Pregnancy
* History of sensitivity to secretin
* Unwilling or unable to sign informed consent